FierceBiotech's Drug Development Forum Attracts Executive-Level Biopharma Professionals for Second Annual Conference in Boston This September

Monday, June 19, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, June 19, 2017 /PRNewswire/ -- Attendees of FierceBiotech's 2nd Annual Drug Development Forum

will obtain essential funding strategies and more productive R&D through executive-level networking opportunities. Convening at the Renaissance Boston Waterfront Hotel September 25–27, 2017, the conference draws together the industry's top decision
makers to help guide to success throughout the entire lifecycle — both for products and businesses. 

"Our primary objective behind this conference is to build a program for the industry, by the industry and we've been working very closely with our advisory board, our readers, and key industry leaders to develop a program that digs into the real issues facing our industry," said Rebecca Willumson, VP and Publisher of FierceBiotech.

Some sample sessions include:

Meet Increasing Demands for Real-World Evidence Donald Bergstrom, CMO, MERSANA THERAPEUTICS

Shorten the Path From Preclinical to Clinical PhasesJohn Hohneker, Executive Vice President, Head of R&D, FORMA THERAPEUTICS Sara Nochur, Senior Vice President, Regulatory Affairs, ALNYLAM PHARMACEUTICALS Richard Gregory, CSO, IMMUNOGENTimothy Lowinger, CSO, MERSANA THERAPEUTICS

Enable Flexibility, Creativity and Independence in Partnerships Between Large and Small Biotech CompaniesMichael Bailey, CEO, AVEO ONCOLOGYChandra Ramanathan, Vice President and Head, East Coast Innovation Center, BAYERCynthia Schwalm, President, North American Commercial Operations, IPSENRich Murray, CEO, JOUNCE THERAPEUTICS

Add Orphan Indications to Accelerate DevelopmentKrishna Menon, CSO, CELLCEUTIXJohn Lee, CMO, PHASEBIO PHARMACEUTICALS

How to Succeed in Novel Deal Structures (Even If They're Trying)Richard Brudnick, Executive Vice President, Business Development, BIOVERATIV Michael Aberman, Vice President, Strategy and Investor Relations, REGENERON Lindsay Rosenwald, CEO, FORTRESS BIOTECH

ABOUT FIERCEBIOTECHFierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more.  An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories.  www.fiercebiotech.com

ABOUT EXL EVENTSExL Events, a division of Questex, LLC, is the industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe, Latin America and additional markets. www.exlevents.com

CONTACTFor information on exhibiting and sponsorship opportunities, please contact Andrew Sinetar at 212-400-6237  or asinetar@exlevents.com.

RELATED LINKwww.FierceDrugDevForum.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fiercebiotechs-drug-development-forum-attracts-executive-level-biopharma-professionals-for-second-annual-conference-in-boston-this-september-300475241.html

SOURCE ExL Events, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook